Objective: To determine the efficacy of an automated, interactive, telephone-based health communication intervention for improving glaucoma treatment adherence among patients in 2 hospital-based eye clinics.
I
N THE UNITED STATES, GLAUcoma affects more than 2 million adults who are older than 40 years.
1 Its prevalence is higher among black populations and increases with age. 2, 3 Substantial personal and economic costs are associated with the progression of glaucoma. 4, 5 Personal, nonfinancial costs and consequences of vision loss due to glaucoma include loss of independence (eg, limitations in driving and reading abilities) 6, 7 and lower quality of life. 8 Medication use can reduce the progressive visual field loss caused by glaucoma, but nonadherence with glaucoma medication remains a primary treatment challenge. Rates of patient-reported adherence with glaucoma medication range from approximately 50% to 55%, 9, 10 and rates of electronically monitored adherence range from 30% to 60%. 11, 12 Adherence to regular follow-up medical appointments is also critical for effective management of glaucoma. To our knowledge, only a few studies [13] [14] [15] [16] have reported adherence with follow-up appointments. An analysis of Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System data among adults aged 40 years or older with glaucoma in 19 states found that 12% of these adults self-reported missing recommended follow-up visits.
Adherence has been found to be poorer among blacks and among those who do not understand the importance of long-term treatment and follow-up visits. 16 Interventions to improve glaucoma treatment adherence and its determinants 18, 19 are needed. A variety of educational materials, services, resources, tools, and devices are available to support patient adherence to glaucoma treatment, 20 but evidence regarding their effectiveness is lacking. The current evidence base regarding any single intervention approach is specifically constrained by the availability of only a few controlled trials in this area, by small sample sizes, and by limited duration followup. 21, 22 There is a need for larger and longer-duration studies of interventions to improve glaucoma patients' treatment adherence with both medication and follow-up appointments.
The Interactive Study to Increase Glaucoma Adherence to Treatment (I-SIGHT) randomized controlled trial was conducted to determine the efficacy of an automated, interactive, telephone-based health communication intervention and accompanying printed materials for improving glaucoma treatment adherence among patients in 2 hospital-based eye clinics. This article reports the results of the I-SIGHT trial on adherence to glaucoma medications, appointment attendance, and medication refills 1 year after baseline assessments.
METHODS

DESIGN OVERVIEW AND PROCEDURES
We evaluated the I-SIGHT intervention in a randomized controlled trial with telephone interviews administered to all participants at baseline, 6, 9, and 12 months. The I-SIGHT intervention is a telephone and print-based intervention that is individually tailored to a participant's knowledge, attitudes, and behaviors; psychosocial predictors of adherence; health literacy; race and culture; and prescribed medication regimen. Outcome measures of treatment adherence included self-reported data on adherence knowledge, attitudes, and behaviors and administrative data on medication taking, prescription drug renewals, and appointment adherence. The study protocol was approved by the Emory University and University of Pennsylvania institutional review boards and by the research oversight committees of the 2 participating hospitals and was fully compliant with the Health Insurance Portability and Accountability Act. 
SAMPLE AND SETTING
Study participants were patients recruited from 2 eye clinics located in hospitals in the southeastern United States: a Veterans Affairs (VA) hospital and a large public hospital. To be eligible for the study, participants had to meet the following criteria: receive treatment for their eye condition at 1 of the 2 participating eye clinics; be between the ages of 18 and 80 years; be white or black/African American; have a home or cellular telephone; speak and understand English; be diagnosed with glaucoma or ocular hypertension for at least 1 year; be prescribed daily doses of topical glaucoma treatments for at least the past year; not have had eye surgery within the past 3 months; have better than 20/200 vision in at least 1 eye; and be able to read or have someone who can help them with reading printed materials. Participants also had to acknowledge nonadherence, in the past year, with medication taking, obtaining refills, or clinic appointments in a screening interview. Potentially eligible participants were identified through chart reviews and physician referrals and were contacted by mail and then by telephone for further eligibility screening and informed consent to participate.
Using a 2-group design and a planned sample size of 300 patients, we have adequate power (Ͼ80%) to detect a 15 to 20 percentage point difference in adherence with glaucoma treatment at 12-month follow-up. We used the software program Power and Precision by Borenstein et al 23 to assess statistical power.
RANDOMIZATION
After completing the baseline interview, each participant was randomized into either the control or intervention group (with a 1:1 ratio). A random number generator was used in Excel (Microsoft), and participants were randomized in blocks of 10. The sequence was generated in advance by the research project manager, and participants were assigned in the order that they were enrolled. Randomization was stratified by clinical site because of expected differences in sex, race, and educational level between the sites. Research interviewers were not masked to assignment because it was necessary to determine treatment group participants' preferences for intervention delivery (eg, preferred telephone number and time of day). Medical providers were masked to assignment because they were not directly involved in the trial.
DESCRIPTION OF THE INTERVENTION
The treatment group received a tailored telephone intervention and tailored printed materials. The control group received usual care, including the recommendation for medical appointments and prescription refills on each patient's physicianprescribed schedule. Both groups received birthday cards from the study team.
The telephone intervention consisted of 12 educational telephone calls over a 9-month period: a call every 2 weeks during months 1 and 2; a call every 3 weeks during months 3, 4, and 5; and a call every 4 weeks during months 6, 7, 8, and 9. The objectives of the calls were to provide individually tailored messages to encourage adherence with medication taking, appointment keeping, and refills; provide information about glaucoma; and intervene on barriers to adherence. The intervention was provided in 2009 and 2010.
The telephone-based health communication intervention utilized interactive voice recognition technology to facilitate interest, participation, and interaction with call recipients and to standardize the content and delivery of the calls. Participants had the option to respond orally or use a telephone keypad. Telephone calls were primarily outbound, but participants had the option to call into the system if they missed a call. After 5 days of unsuccessful attempts to deliver a call, a reminder card was sent requesting that the participant call in to receive his or her message. For each missed call (10 days of unsuccessful attempts), contact was made with participants to ensure that accurate contact information was on file.
Each call was structured to include a salutation (ie, greeting, participant verification, and introduction); a medication regimen review (ie, confirmation of medication regimen and assessment of adherence); the core conversation, with tips to address barriers to adherence (eg, a tip on administering drops); general glaucoma information; and a closing (ie, a synopsis of the call and a reminder to take medication). Each intervention call was recorded for quality assurance, and the results of each attempted call were reviewed weekly for each participant.
In addition to the intervention calls, participants received printed materials after each phone call. The printed materials were designed to reinforce tips and strategies to improve treatment adherence, to provide additional glaucoma information, and to be easy to review and reference at the participant's own time and convenience. They were designed as 1-page, doublesided flyers written in large print at an 8th-grade reading level. Written materials were mailed 1 week after completion of a telephone call.
DATA SOURCES: INTERVIEWS, CHART REVIEWS, PHARMACY RECORDS Baseline and Follow-up Interviews
At the time of enrollment in the study, participants in both the intervention and control groups were interviewed over the telephone by a trained research assistant. This structured interview included questions about the demographic and background characteristics of the patient; the facilitators of and the barriers to medication taking, proper medication administration, refills, and appointment keeping; medication regimen complexity; glaucoma knowledge, information-seeking behavior, and health literacy; and psychosocial factors such as selfefficacy, outcome expectancies, quality of life, and social support.
The follow-up interviews had the same structure as the baseline interview and were conducted by telephone at 6, 9, and 12 months. Each follow-up interview measured glaucoma treatment adherence (ie, medication taking, refills, and appointments). The 9-month interview included questions for participants in the treatment group to evaluate the intervention. The final interview occurred at 12 months and measured glaucoma treatment adherence and asked about the facilitators of and the barriers to glaucoma treatment adherence and about psychosocial factors (including self-efficacy and outcome expectancies). Interviews lasted between 20 and 45 minutes, and participants were compensated with a $25 gift card for their time and effort expended on each interview.
The adherence measure, developed and pilot tested by the I-SIGHT team, assessed adherence with medication taking, refills, and appointment keeping by self-report. Participants were considered nonadherent with medication taking if they reported missing doses of any glaucoma medication within 1 month of the interview. 24 Levels of medication-taking nonadherence were further differentiated by missed doses within 7 days, 2 weeks, or 1 month of the interview. Nonadherence with refills was defined as running out of any glaucoma medication and subsequently missing a dose within a specified time frame (ie, 1 year prior to the baseline interview; 6 months prior to 6-month interview; and 3 months prior to the 9-and 12-month interviews). Appointment-keeping nonadherence was indicated by self-report of missing a glaucoma treatment appointment and not rescheduling during the specified time frame. Self-report of nonadherence in any of these 3 areas classified the participant as nonadherent with glaucoma treatment.
Chart, Administrative, and Pharmacy Records
Eye clinic medical charts were reviewed at baseline, 6, 9, and 12 months to obtain objective data on nonadherence with each aspect of treatment and to supplement self-reported data. Medication-taking nonadherence by chart review was identified through physician notes about missed doses or issues with medication-taking consistency. Refill nonadherence was defined as pharmacy records indicating failure to refill any glaucoma medication prescription within a 1-month period after it was prescribed or as a physician note on refill nonadherence. Nonadherence with appointment keeping was assessed as any missed appointment within the specified time frame that was not rescheduled within 3 months or as a physician note on appointment-keeping nonadherence. Three months was chosen as the allowable time to make up an appointment because the participating clinics generally have a wait time of 3 months to schedule an appointment. Adherence data from data abstractions were coded independently by 2 raters who met in cases of disagreement to resolve discrepancies.
PROCESS EVALUATION
We obtained data on patients' evaluations of the intervention from all treatment group participants who completed the 9-month telephone interview. Close-ended questions measured the likability/interest, acceptability, and usefulness of the telephone interviews and the printed material. Sample questions included the following: How easy to understand were the telephone calls/print materials? How much did you like the information we sent you in the written materials?
In addition, we sought to evaluate whether participants had any logistical problems using the interactive voice recognition technology by asking the following question: How much did you have a problem with the system recognizing your voice? The responses to this close-ended question were in the form of a 5-point Likert scale, ranging from 1 (not at all) to 5 (a lot). To conclude the process evaluation, we asked whether they would recommend this study to others.
STATISTICAL ANALYSIS
Descriptive statistics were used to describe the study participants, to compare characteristics across treatment groups and study sites, and to summarize participants' reactions to the intervention. The 12-month interview and chart data were used as the main study end points. For most patients, an adherence measure at 12 months was available (Ͼ90% for all selfreported measures, chart refills data, and chart appointment keeping). However, if the 12-month value on any of the 3 selfreported indicators and the 3 chart indicators of adherence was not available, the 9-month value was used. If the 9-month value was not available, the 6-month value was used. If none of those 3 values were available for a given indicator, the patient was not included in that analysis. Thus, if a patient was nonadherent at 6 months, adherent at 9 months, and adherent at 12 months, then they were considered adherent at their last visit.
The 2 treatment groups were compared on change in the percentage of adherent patients between the baseline visit and the follow-up visit using a longitudinal logistic regression model fit with a generalized linear model. 25 The model included a term for treatment, for visit, and for the interaction of treatment and visit. The comparison between the groups is based on the P value for the interaction term. A separate model was fit for each of the adherence measures. A P value of less than .05 was considered to be statistically significant. No adjustments were made for multiple testing. A stratified analysis by clinical site (VA hospital vs public hospital) was also conducted. The statistical calculations were performed using PROC GENMOD of SAS version 9.2 (SAS Institute Inc). To examine a possible doseresponse effect within the treatment group, a comparison of the proportion of patients adherent at 12 months was performed between those who received all 12 intervention calls and those who did not, using a 2 test.
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PARTICIPANT CHARACTERISTICS
Our Figure shows the flowchart of potentially eligible, enrolled, randomly assigned patients and those completing the 12-month interview. Among the 850 potentially eligible patients, there were more ineligible participants from the VA hospital than from the public hospital, and there were more refusals from public hospital patients than from VA hospital patients. Participants in the trial (Table 1) had a mean (SD) age of 62.6 (10.2) years and were mostly in the age range of 50 to 69 years. There were no significant differences between treatment groups on background characteristics. Just over 60% were male participants, with men comprising more than 90% of participants from the VA hospital and only 31% of participants from the public hospital (PϽ.001). More than 90% of the participants were black, with nearly all the white participants coming from the VA hospital. The VA hospital participants were significantly more educated than the public hospital participants (PϽ.001 for both). The VA hospital patients were more likely to be married and had a higher income compared with the public hospital patients.
More than half the participants were taking 2 or more glaucoma medications, and more than half had made 3 or more eye clinic visits during the preceding year. More than 90% of participants were nonadherent in at least 2 of the 3 areas examined (taking medication, refilling medication, and keeping appointments). Based on selfreported data, nearly all were nonadherent with taking medication (96.2%), followed by refilling medication (91.0%) and keeping appointments (65.1%). Chart data showed similarly high nonadherence rates: nonadherence with taking medication was the highest at 97.7%, followed by nonadherence with refilling medication at 96.1% and missing appointments at 62.1%. The 2 treatment groups did not differ in the number of medications, in the number of appointments, or in adherence rates. Table 2 shows the adherence outcomes by treatment group for self-reports and chart reports. Adherence increased substantially for all measures and in both groups (all time effects significant at PϽ.01). Self-reported medication adherence increased from 10.2% to 30.2% in the treatment group and from 13.5% to 27.0% in the control group (the timeϫtreatment interaction was not significant). For 4 of the 6 outcomes, the treatment group improvements were 4 to 10 percentage points greater than for the control group, but timeϫ treatment interactions did not reach statistical significance. A stratified analysis by clinical site revealed similar results, with no treatment group effect among participants at either site. There was no difference in the percentage of patients who were adherent at 12 months between those who received all 12 telephone calls and those who did not; however, telephone call completion was very high: 58.7% received all 12 calls, and 80.7% received at least 10 calls.
ADHERENCE OUTCOMES
PARTICIPANTS' REACTIONS TO THE INTERVENTION
Participants' reactions to the tailored, automated telephone calls and written materials were very positive. More Figure. Consolidated Standards of Reporting Trials diagram of eligibility, participation, group assignment, and study completion of the Interactive Study to Increase Glaucoma Adherence to Treatment trial. The 12-month follow-up data reflect the more than 90% of participants who completed the 12-month interview combined with data collected from the 6-and 9-month interviews for those without 12-month data.
ARCH OPHTHALMOL PUBLISHED ONLINE JUNE 11, 2012 WWW.ARCHOPHTHALMOL.COM E4 than 85% of respondents rated the calls as easy to understand, and 78% to 85% said the calls were interesting, personally relevant, and helpful. The written materials were rated as easy to read by 84.6% of respondents, as personally relevant by 78.3%, and as attractive by 72.7%. Most liked the interactive features, did not have diffi- culty with the system recognizing their voice, and preferred to speak than use the keypad. All respondents said they would recommend the program to other people with glaucoma.
COMMENT
A statistically significant increase for all adherence measures was noted in both the treatment group and the control group in the I-SIGHT trial. The treatment group had greater improvements in adherence in 4 of 6 categories, but this did not reach statistical significance. A previous study 22 of an intervention program to improve glaucoma adherence to medication noted an intervention effect similar in size to those noted in both of our study groups. Although it is possible that the adherence measures chosen and piloted for this study were too insensitive to capture a modest treatment effect, it is difficult to explain the statistically significant effect in the control group without questioning whether other studyrelated factors accounted for the changes. There may have been a selection bias that contributed to a placebo effect in the control group. The "control" patients may have already been highly motivated to seek further knowledge or involvement in managing their glaucoma. Furthermore, all participants in the I-SIGHT trial completed a baseline interview prior to being randomly assigned and were reinterviewed at 6, 9, and 12 months. The trial retention rate was very high owing in part to study interviewers who were very successful at establishing a rapport with the participants. The fact that interviewers were not masked to treatment group status is a limitation, although the use of close-ended questions likely limited any potential for bias. Another possible explanation for the statistically significant increase in adherence in both groups is that adherence is dynamic and varies more throughout the course of a year than previously believed.
Treatment adherence in glaucoma is complex and is influenced by many determinants. 22 Nonadherence with glaucoma medication is common, ranging from 5% to 80%. [26] [27] [28] Patients with poor health literacy and black/ African American patients have been noted to have poor adherence with glaucoma therapy and greater disease progression. 29, 30 Interventions to improve adherence require multifaceted approaches. 31 A recent review 21 of the efficacy of glaucoma medication adherence interventions identified only 7 randomized, controlled trials and a total of 8 intervention studies that met the review's inclusion criteria. Gray and colleagues 21 concluded that small sample sizes (ranging from 13 to 202 across the studies), missing data, and shortterm follow-up durations (ranging from 4 to 12 weeks) greatly limit the extant evidence in support of any one intervention approach. 21 Furthermore, most published studies have investigated glaucoma adherence with medication taking, 22 with few studies also measuring clinic visit adherence. The I-SIGHT trial addressed these limitations by (1) developing and testing a multicomponent intervention designed to address a variety of adherence determinants, (2) measuring medication taking, refills, and appointment keeping adherence outcomes, and (3) evaluating efficacy at 12 months with an adequately large sample to detect small to moderate effect sizes.
The I-SIGHT trial evaluated an innovative approach to glaucoma medication adherence, appointment keeping, and refills in nonadherent patients using an automated, patient-centered, and interactive telephonebased intervention strategy. Nonadherence determinations were based on self-report and on chart abstraction of medication taking, pharmacy refill data, and clinic appointment keeping. Interestingly, there were some differences between self-reported and chart data, with nonadherence rates being lower based on administrative data. This is most likely due to the fact that chart notes may not have indicated medication nonadherence, especially if the patient also missed his or her appointment. It would be a greater concern if selfreported rates of nonadherence were found to be lower than chart data rates of nonadherence, which would suggest that patients may have been reluctant to report their nonadherence to research interviewers. This underscores the importance of careful pretesting and the use of nonjudgmental questions in the adherence measure interview, although there is no perfect way to measure adherence. In other studies, 26 ,32 physician chart notes have been shown to correlate with pharmacy refill records and monitored adherence.
Interactive voice recognition has been used successfully to improve treatment adherence in other chronic conditions such as asthma. 33 The voice recognition system allows participants to react to questions and prompts them to use their own voice, allowing for interactivity and active engagement. Telephones have been found to be an effective channel for delivering tailored interventions. [34] [35] [36] Using a 2-armed randomized trial, I-SIGHT enrolled 312 participants from 2 clinical sites. There were no significant differences between the treatment and control groups in background characteristics. The majority of participants in this study were black/African American and were of a low socioeconomic and educational status. The I-SIGHT trial confirmed poor medication and appointment adherence rates in these patients, highlighting the need for effective strategies to improve glaucoma health literacy and adherence to treatment. However, the study findings may not be generalizable to private practice or other nonclinic settings.
The findings of the I-SIGHT trial suggest that motivated patients participating in an ongoing clinical trial may improve their adherence, even without tailored messages, but because there was not an untailored "attention intervention" condition, this needs to be tested in future research. New technologies, such as interactive voice recognition and electronic reminder devices, may play a supportive role in the effort to improve adherence in patients with glaucoma, but further study is warranted.
